prec human primary prostate epithelial cell line  (ATCC)

Journal: Frontiers in Pharmacology

Article Title: MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3

doi: 10.3389/fphar.2021.667474

Figure Lengend Snippet: Up-regulation of VEGFR-3 in human prostate cancer PC-3 cells. The protein expression of VEGFRs was examined in human prostate epithelial PrEC cells and prostate cancer LNCaP (androgen-dependent/weakly metastatic), PC-3 (androgen-independent/highly bone metastatic), and DU145 (androgen-independent/moderate brain metastatic) cells by Western blotting. (A) Representative blots of VEGFR-1, VEGFR-2, and VEGFR-3 in PrEC, LNCaP, PC-3, and DU145 cells. β-actin was used as an endogenous marker. (B) Expression levels of VEGFR-1, VEGFR-2, and VEGFR-3 in PrEC, LNCaP, PC-3, and DU145 cells ( n = 4–11). The expression levels of VEGFRs were normalized by that of β-actin. Note that the expression level of VEGFR-3 was higher in PC-3 cells than in PrEC, LNCaP, and DU145 cells. Data are presented as means ± S.D.

Article Snippet: The human prostate epithelial cell line, PrEC, was purchased from Lonza (Walkersville, MD, United States).

Techniques: Expressing, Western Blot, Marker

Journal: Frontiers in Pharmacology

Article Title: MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3

doi: 10.3389/fphar.2021.667474

Figure Lengend Snippet: VEGF-C levels in human prostate cancer cells. The levels of VEGF-C in the culture media of human prostate epithelial PrEC cells and prostate cancer LNCaP, PC-3, and DU145 cells were measured using the human VEGF-C Quantikine ELISA kit. Note that larger amounts of VEGF-C were secreted from PC-3 cells than from PrEC, LNCaP, and DU145 cells ( n = 10). Data are presented as means ± S.D. ** p < 0.01 vs. PrEC, LNCaP, or DU145 cells (Scheffé’s test following ANOVA).

Article Snippet: The human prostate epithelial cell line, PrEC, was purchased from Lonza (Walkersville, MD, United States).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Pharmacology

Article Title: MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3

doi: 10.3389/fphar.2021.667474

Figure Lengend Snippet: Inhibitory effects of MAZ51 on the proliferation of human prostate cancer cells. The effects of MAZ51 on the cell viability and proliferation of human prostate epithelial PrEC cells and prostate cancer LNCaP, PC-3, and DU145 cells using MTT and BrdU assays, respectively. (A) Time-dependent cell growth of PrEC, LNCaP, PC-3, and DU145 cells ( n = 9–16). (B) The effects of MAZ51 for 48 h on the viability of PrEC, LNCaP, PC-3, and DU145 cells ( n = 8–34). The IC 50 values of MAZ51 on the viabilities of PrEC, LNCaP, PC-3, and DU145 cells were 7.0, 6.0, 2.7, and 3.8 μM, respectively. (C) The effects of 100 nM GSK690693 (an Akt inhibitor) for 48 h on the viability of PrEC, LNCaP, PC-3, and DU145 cells ( n = 12–18). (D) The effects of VEGFR2 Kinase Inhibitor I for 48 h on the viability of PrEC, LNCaP, PC-3, and DU145 cells ( n = 12–24). (E) The effects of MAZ51 for 48 h on the proliferation of PC-3 cells ( n = 12). (F) The effects of 50 and 100 nM VEGFR-3 siRNA for 48 h on the proliferation of PC-3 cells ( n = 16–24). Data are presented as means ± S.D. * p < 0.05, ** p < 0.01 vs. 6 h, 0 μM drug, or control siRNA; # p < 0.05, ## p < 0.01 vs. PrEC cells (Scheffé’s test following ANOVA).

Article Snippet: The human prostate epithelial cell line, PrEC, was purchased from Lonza (Walkersville, MD, United States).

Techniques: Control